Acacia, CombiMatrix | GenomeWeb

Acacia, CombiMatrix

Premium

Acacia subsidiary CombiMatrix has created what is believed to be the first microarray based on the Severe Acute Respiratory Syndrome coronavirus, the company said.

CombiMatrix said the arrays were fabricated “within 48 hours” of publication of the coronavirus genome sequence believed to be responsible for SARS. Researchers at the US Centers for Disease Control and at the Michael Smith Genome Sciences Center in Canada independently announced early this week that they had sequenced the coronavirus genome.

 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.